Jiajia Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiajia Wang has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Ou Wang
Department of Endocrinology, NHC Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100730
6 shared publications - An Song
Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Translational Medicine Center, State Key Laboratory of Complex Severe and Rare Diseases, National Health Commission Key Laboratory of Endocrinology, Beijing 100730, China
5 shared publications - Xiaoping Xing
Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
5 shared publications - Mei Li
Department of Endocrinology, NHC Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100730
4 shared publications - Weibo Xia
Department of Endocrinology, NHC Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100730
3 shared publications Yan Jiang
Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission;Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College 1
3 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Bioscientifica in Endocrine Connections
Real-world biochemical control in Chinese adult-onset hypoparathyroidism patients
Hypoparathyroidism(HypoPT) is rare, and real-world studies of biochemical control in affected patients are limited. This study aimed to analyze biochemical control in a large cohort of patients with adult-onset chronic HypoPT. Subjects were selected from outpatients followed at our center from June 2009 to March 2023. Proportion of measurements in/above/below the target range (MIR/MAR/MBR) and estimated time in/above/below the target range (TIR/TAR/TBR) were calculated. A total of 114 post-surgical (PS-HP) and 64 non-surgical (NS-HP) patients were enrolled, with a median follow-up of 82.5(45.0,108.0) months. The MIR/TIR were 70∼80% for serum calcium (Ca), around 40% for serum phosphorus(P), 80∼90% for 24-hour urine calcium(24hUCa), nearly 100% for calcium-phosphate products, 50∼64% for combined index 1(serum Ca and 24hUCa), and 20∼25% for combined index 2(all four indices). A total of 21 episodes of hypercalcemia occurred in 7 (3.93%) patients among the total 3455 measurements (0.61%). Compared to PS-HP patients, NS-HP patients showed poorer control of serum P, 24hUCa and combined indices. Serum Ca at diagnosis was positively associated with serum Ca TIR (β=21.15, P<0.05). Calcitriol dosage recorded at the last follow-up was negatively associated with TIR of serum Ca (β=-35.30, P<0.01) and 24hUCa (β = –66.19, P < 0.05). Hydrochlorothiazide use recorded at the last follow-up was associated with a 20.99% lower 24hUCa TIR (P < 0.001). Male patients showed higher serum P TIR than female (β1=28.14, P<0.001; β2=16.96, P<0.05). The control of serum Ca and 24hUCa was acceptable, whereas serum P and overall indices were suboptimal in our center. NS-HP patients showed poorer biochemical control than PS-HP patients and need more attention.
- 28 October 2026
- Published by Bioscientifica in Endocrine Connections
Open AccessReal-world biochemical control in Chinese adult-onset hypoparathyroidism patients
Hypoparathyroidism(HypoPT) is rare, and real-world studies of biochemical control in affected patients are limited. This study aimed to analyze biochemical control in a large cohort of patients with adult-onset chronic HypoPT. Subjects were selected from outpatients followed at our center from June 2009 to March 2023. Proportion of measurements in/above/below the target range (MIR/MAR/MBR) and estimated time in/above/below the target range (TIR/TAR/TBR) were calculated. A total of 114 post-surgical (PS-HP) and 64 non-surgical (NS-HP) patients were enrolled, with a median follow-up of 82.5(45.0,108.0) months. The MIR/TIR were 70∼80% for serum calcium (Ca), around 40% for serum phosphorus(P), 80∼90% for 24-hour urine calcium(24hUCa), nearly 100% for calcium-phosphate products, 50∼64% for combined index 1(serum Ca and 24hUCa), and 20∼25% for combined index 2(all four indices). A total of 21 episodes of hypercalcemia occurred in 7 (3.93%) patients among the total 3455 measurements (0.61%). Compared to PS-HP patients, NS-HP patients showed poorer control of serum P, 24hUCa and combined indices. Serum Ca at diagnosis was positively associated with serum Ca TIR (β=21.15, P<0.05). Calcitriol dosage recorded at the last follow-up was negatively associated with TIR of serum Ca (β=-35.30, P<0.01) and 24hUCa (β = –66.19, P < 0.05). Hydrochlorothiazide use recorded at the last follow-up was associated with a 20.99% lower 24hUCa TIR (P < 0.001). Male patients showed higher serum P TIR than female (β1=28.14, P<0.001; β2=16.96, P<0.05). The control of serum Ca and 24hUCa was acceptable, whereas serum P and overall indices were suboptimal in our center. NS-HP patients showed poorer biochemical control than PS-HP patients and need more attention.
- 9 March 2026
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (8) , 1-13
Clinical characteristics of chinese patients with autosomal dominant hypocalcemia type 1: a single-center study
- 9 March 2026
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (8) , 1-13
Clinical characteristics of chinese patients with autosomal dominant hypocalcemia type 1: a single-center study
- Open Access
- 13 March 2025
- Published by Elsevier in Osteoporosis and Sarcopenia
- Vol. 11 (1) , 22-28
Two novel rare variants in the PTH gene found in patients with hypoparathyroidism
- 13 March 2025
- Published by Elsevier in Osteoporosis and Sarcopenia
- Vol. 11 (1) , 22-28
Open AccessTwo novel rare variants in the PTH gene found in patients with hypoparathyroidism
- 3 March 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
The Efficacy and Safety of Denosumab for Treating Hypercalcemia in Primary Hyperparathyroidism: A Retrospective Study
Context: Denosumab is approved for treating hypercalcemia of malignancy, but data on its efficacy for hypercalcemia related to primary hyperparathyroidism (PHPT) are limited. Objective: To compare the efficacy and safety of denosumab with zoledronic acid in PHPT-related hypercalcemia. Methods: We retrospectively collected data from 29 PHPT patients with moderate/severe hypercalcemia (corrected serum calcium [CSC] ≥ 3.0 mmol/L) treated with denosumab (60 or 120 mg; Dmab group) and CSC-matched 29 PHPT patients treated with zoledronic acid (4 mg; ZA group). The primary efficacy outcome was the change of CSC (ΔCa), while secondary outcomes included the response proportion, time to response, and duration of response. Safety data were also collected. Results: Both groups showed significant reductions in CSC levels (Dmab: 3.37 ± 0.37 mmol/L to 2.64 ± 0.33 mmol/L, P < .01; ZA: 3.41 ± 0.32 mmol/L to 2.57 ± 0.23 mmol/L, P < .01), with similar ΔCa. In the Dmab group, 82.8% (24/29) responded with CSC levels below 3.0 mmol/L, and 72.4% (21/29) achieved complete response (CR, serum CSC less than 2.7 mmol/L), comparable to the ZA group. The time to CR was shorter for ZA (3.0 vs 7.0 days, P < .01), while Dmab had a longer duration of response (19.0 vs 13.0 days, P = .02). Hypocalcemia occurred in 6.9% (2/29, both with chronic kidney disease stage 3b) of Dmab patients, while none in the ZA group. Conclusion: A single 60-mg dose of denosumab effectively reduces serum calcium levels in PHPT patients with moderate/severe hypercalcemia, at least maintaining efficacy for a median of nearly 3 weeks without serious adverse events.
- 3 March 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
The Efficacy and Safety of Denosumab for Treating Hypercalcemia in Primary Hyperparathyroidism: A Retrospective Study
Context: Denosumab is approved for treating hypercalcemia of malignancy, but data on its efficacy for hypercalcemia related to primary hyperparathyroidism (PHPT) are limited. Objective: To compare the efficacy and safety of denosumab with zoledronic acid in PHPT-related hypercalcemia. Methods: We retrospectively collected data from 29 PHPT patients with moderate/severe hypercalcemia (corrected serum calcium [CSC] ≥ 3.0 mmol/L) treated with denosumab (60 or 120 mg; Dmab group) and CSC-matched 29 PHPT patients treated with zoledronic acid (4 mg; ZA group). The primary efficacy outcome was the change of CSC (ΔCa), while secondary outcomes included the response proportion, time to response, and duration of response. Safety data were also collected. Results: Both groups showed significant reductions in CSC levels (Dmab: 3.37 ± 0.37 mmol/L to 2.64 ± 0.33 mmol/L, P < .01; ZA: 3.41 ± 0.32 mmol/L to 2.57 ± 0.23 mmol/L, P < .01), with similar ΔCa. In the Dmab group, 82.8% (24/29) responded with CSC levels below 3.0 mmol/L, and 72.4% (21/29) achieved complete response (CR, serum CSC less than 2.7 mmol/L), comparable to the ZA group. The time to CR was shorter for ZA (3.0 vs 7.0 days, P < .01), while Dmab had a longer duration of response (19.0 vs 13.0 days, P = .02). Hypocalcemia occurred in 6.9% (2/29, both with chronic kidney disease stage 3b) of Dmab patients, while none in the ZA group. Conclusion: A single 60-mg dose of denosumab effectively reduces serum calcium levels in PHPT patients with moderate/severe hypercalcemia, at least maintaining efficacy for a median of nearly 3 weeks without serious adverse events.
- 4 August 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (1) , 135-142
Trabecular Bone Score as a More Sensitive Tool to Evaluate Bone Involvement in MEN1-related Primary Hyperparathyroidism
Context: The skeletal involvement of multiple endocrine neoplasia type 1-related primary hyperparathyroidism (MHPT) is not exactly the same as that of sporadic primary hyperparathyroidism (SHPT). Trabecular bone score (TBS) as a texture parameter has been reported to reflect trabecular bone damage. Objective: This study aimed to compare the clinical characteristics, especially the skeletal involvement, between patients with MHPT and SHPT. Methods: The clinical characteristics were retrospectively collected in 120 patients with MHPT and compared with 360 patients with SHPT in the same period. Dual-energy X-ray absorptiometry were conducted in some patients with MHPT, in whom bone mineral density (BMD) and calculated TBS derived from lumbar spine dual-energy X-ray absorptiometry images were compared with those of patients with SHPT. Results: Although the duration of disease in the MHPT group was longer, the age at hospital visit was significantly lower than that in the SHPT group (43.5 [interquartile range, 31.5-52.0] vs 52.0 [interquartile range, 40.5-61.0], P < .001). The proportion of skeletal involvement in the MHPT group was significantly lower. However, in the subgroup of MHPT cases (n = 86) with data of BMD, there was no significant difference in skeletal involvement from SHPT cases matched for gender and age. Although the BMD and TBS in the lumbar spines of patients with MHPT were lower than those of patients with SHPT (BMD: 0.91 ± 0.18 g/cm2 vs 1.01 ± 0.17 g/cm2; TBS: 1.22 ± 0.14 vs 1.29 ± 0.11, P < .001). According to TBS, among 34 patients with MHPT with normal BMD, 15 patients had bone microstructure damage. Conclusion: The cancellous bone microarchitecture was more severely damaged in patients with MHPT according to TBS, which suggested that TBS could be a sensitive supplemental index in addition to BMD to identify bone-involvement risk in patients with MHPT.
- 4 August 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (1) , 135-142
Trabecular Bone Score as a More Sensitive Tool to Evaluate Bone Involvement in MEN1-related Primary Hyperparathyroidism
Context: The skeletal involvement of multiple endocrine neoplasia type 1-related primary hyperparathyroidism (MHPT) is not exactly the same as that of sporadic primary hyperparathyroidism (SHPT). Trabecular bone score (TBS) as a texture parameter has been reported to reflect trabecular bone damage. Objective: This study aimed to compare the clinical characteristics, especially the skeletal involvement, between patients with MHPT and SHPT. Methods: The clinical characteristics were retrospectively collected in 120 patients with MHPT and compared with 360 patients with SHPT in the same period. Dual-energy X-ray absorptiometry were conducted in some patients with MHPT, in whom bone mineral density (BMD) and calculated TBS derived from lumbar spine dual-energy X-ray absorptiometry images were compared with those of patients with SHPT. Results: Although the duration of disease in the MHPT group was longer, the age at hospital visit was significantly lower than that in the SHPT group (43.5 [interquartile range, 31.5-52.0] vs 52.0 [interquartile range, 40.5-61.0], P < .001). The proportion of skeletal involvement in the MHPT group was significantly lower. However, in the subgroup of MHPT cases (n = 86) with data of BMD, there was no significant difference in skeletal involvement from SHPT cases matched for gender and age. Although the BMD and TBS in the lumbar spines of patients with MHPT were lower than those of patients with SHPT (BMD: 0.91 ± 0.18 g/cm2 vs 1.01 ± 0.17 g/cm2; TBS: 1.22 ± 0.14 vs 1.29 ± 0.11, P < .001). According to TBS, among 34 patients with MHPT with normal BMD, 15 patients had bone microstructure damage. Conclusion: The cancellous bone microarchitecture was more severely damaged in patients with MHPT according to TBS, which suggested that TBS could be a sensitive supplemental index in addition to BMD to identify bone-involvement risk in patients with MHPT.
- Open Access
- 8 March 2022
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (21) , 2623-2624
Real-life effectiveness and safety of secukinumab in axial spondyloarthritis: a single-center study
An abstract is unavailable. This article is available as a PDF only.
- 8 March 2022
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (21) , 2623-2624
Open AccessReal-life effectiveness and safety of secukinumab in axial spondyloarthritis: a single-center study
An abstract is unavailable. This article is available as a PDF only.
- 19 July 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (12) , e5054-e5063
Changes in Serum Calcium and Treatment of Hypoparathyroidism During Pregnancy and Lactation: A Single-center Case Series
Background Hypoparathyroidism (hypo-PT) is rare, and studies on hypo-PT, especially during pregnancy and lactation, are limited. Design and Setting This was a retrospective study on a relatively large case series in a single center from mainland China. Methods A total of 19 patients with 25 pregnancies, diagnosed with hypo-PT before pregnancy, were enrolled. Data on clinical characteristics and treatment strategies at onset time and around pregnancy period were collected. Results During pregnancy, except for 2 patients with missing data, 5 patients with 6 pregnancies (6/23, 26.1%) experienced improved hypo-PT condition, defined as an increased serum calcium level; 4 patients with 4 pregnancies (4/23, 17.4%) experienced worsened hypo-PT condition, defined as a more than 0.2 mmol/L decline in the serum calcium level; and 3 patients with 3 pregnancies (3/23, 13.0%) remained in stable hypo-PT condition. The prevalence of adverse pregnancy outcomes was 30.4% (4/23 for preterm delivery; 3/23 for miscarriage). The serum calcium and 24-hour urine calcium levels significantly increased during lactation compared with pregnancy (2.57 ± 0.34 vs 1.99 ± 0.11 mmol/L, P < 0.001; 12.28 ± 5.41 vs 8.63 ± 3.22 mmol/L, P = 0.013), and 5 patients with 5 lactations (5/12, 41.7%) developed hypercalcemia in the first 2 months after delivery. Conclusions Female patients with hypo-PT had different changes in calcium homeostasis and a high prevalence of adverse outcomes during pregnancy. Thus, they should be monitored closely to maintain the optimal serum calcium level. Decreasing drug dosage during the lactation period should be considered to avoid hypercalcemia.
- 19 July 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (12) , e5054-e5063
Changes in Serum Calcium and Treatment of Hypoparathyroidism During Pregnancy and Lactation: A Single-center Case Series
Background Hypoparathyroidism (hypo-PT) is rare, and studies on hypo-PT, especially during pregnancy and lactation, are limited. Design and Setting This was a retrospective study on a relatively large case series in a single center from mainland China. Methods A total of 19 patients with 25 pregnancies, diagnosed with hypo-PT before pregnancy, were enrolled. Data on clinical characteristics and treatment strategies at onset time and around pregnancy period were collected. Results During pregnancy, except for 2 patients with missing data, 5 patients with 6 pregnancies (6/23, 26.1%) experienced improved hypo-PT condition, defined as an increased serum calcium level; 4 patients with 4 pregnancies (4/23, 17.4%) experienced worsened hypo-PT condition, defined as a more than 0.2 mmol/L decline in the serum calcium level; and 3 patients with 3 pregnancies (3/23, 13.0%) remained in stable hypo-PT condition. The prevalence of adverse pregnancy outcomes was 30.4% (4/23 for preterm delivery; 3/23 for miscarriage). The serum calcium and 24-hour urine calcium levels significantly increased during lactation compared with pregnancy (2.57 ± 0.34 vs 1.99 ± 0.11 mmol/L, P < 0.001; 12.28 ± 5.41 vs 8.63 ± 3.22 mmol/L, P = 0.013), and 5 patients with 5 lactations (5/12, 41.7%) developed hypercalcemia in the first 2 months after delivery. Conclusions Female patients with hypo-PT had different changes in calcium homeostasis and a high prevalence of adverse outcomes during pregnancy. Thus, they should be monitored closely to maintain the optimal serum calcium level. Decreasing drug dosage during the lactation period should be considered to avoid hypercalcemia.